1. Home
  2. UTHR vs SGI Comparison

UTHR vs SGI Comparison

Compare UTHR & SGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • UTHR
  • SGI
  • Stock Information
  • Founded
  • UTHR 1996
  • SGI 1846
  • Country
  • UTHR United States
  • SGI United States
  • Employees
  • UTHR N/A
  • SGI N/A
  • Industry
  • UTHR Biotechnology: Pharmaceutical Preparations
  • SGI Home Furnishings
  • Sector
  • UTHR Health Care
  • SGI Consumer Discretionary
  • Exchange
  • UTHR Nasdaq
  • SGI Nasdaq
  • Market Cap
  • UTHR 20.7B
  • SGI 17.4B
  • IPO Year
  • UTHR 1999
  • SGI N/A
  • Fundamental
  • Price
  • UTHR $453.53
  • SGI $79.78
  • Analyst Decision
  • UTHR Buy
  • SGI Strong Buy
  • Analyst Count
  • UTHR 14
  • SGI 6
  • Target Price
  • UTHR $471.50
  • SGI $87.17
  • AVG Volume (30 Days)
  • UTHR 658.6K
  • SGI 1.6M
  • Earning Date
  • UTHR 10-29-2025
  • SGI 11-06-2025
  • Dividend Yield
  • UTHR N/A
  • SGI 0.73%
  • EPS Growth
  • UTHR 16.08
  • SGI N/A
  • EPS
  • UTHR 26.38
  • SGI 1.40
  • Revenue
  • UTHR $3,128,400,000.00
  • SGI $5,993,400,000.00
  • Revenue This Year
  • UTHR $13.82
  • SGI $52.67
  • Revenue Next Year
  • UTHR $5.71
  • SGI $5.74
  • P/E Ratio
  • UTHR $17.26
  • SGI $58.31
  • Revenue Growth
  • UTHR 13.50
  • SGI 23.05
  • 52 Week Low
  • UTHR $266.98
  • SGI $47.48
  • 52 Week High
  • UTHR $479.50
  • SGI $88.15
  • Technical
  • Relative Strength Index (RSI)
  • UTHR 62.66
  • SGI 41.70
  • Support Level
  • UTHR $409.15
  • SGI $81.58
  • Resistance Level
  • UTHR $479.50
  • SGI $84.26
  • Average True Range (ATR)
  • UTHR 13.12
  • SGI 1.65
  • MACD
  • UTHR -1.19
  • SGI -0.44
  • Stochastic Oscillator
  • UTHR 57.20
  • SGI 2.42

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

About SGI Somnigroup International Inc. Common Stock

Somnigroup International Inc is a bedding company, dedicated to improving people's lives through good sleep. With superior capabilities in design, manufacturing, distribution and retail, It delivers breakthrough sleep solutions and serves the evolving needs of consumers in more than 100 countries world-wide through its fully-owned businesses, Tempur Sealy, Mattress Firm and Dreams. The company's portfolio includes the brand such as Tempur-Pedic, Sealy and Stearns & Foster, and its Multinational omnichannel platform enables the company to meet consumers wherever shop, offering a personal connection and innovation to provide a retail experience and tailored solutions.

Share on Social Networks: